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We analyzed the main modalities and clinical outcomes of the early discharge outpatient model in autologous
stem cell transplantation (EDOM-ASCT) for multiple myeloma in Italy. EDOM-ASCT was employed in 382
patients, for a total of 522 procedures, between 1998 and 2012. Our study showed high homogeneity among
centers in terms of inclusion criteria, supportive care, and in hospital readmission criteria. Overall, read-
missions during the aplastic phase occurred in 98 of 522 transplantations (18.8%). The major extra-
hematological complication was neutropenic fever in 161 cases (30.8%), which required readmission in 76
cases. The incidence of severe World Health Organization grade 3 to 4 mucositis was 9.6%. By univariate
analysis, fever, mucositis, altered renal function at diagnosis, second transplantation, and transplantation
performed late in the course of the disease were signiﬁcantly correlated with readmission, whereas fever,
mucositis, altered renal function, and timing of transplantation remained the only independent predictors by
multivariate analysis. Overall, transplantation-related mortality was 1.0%. No center effect was observed in
this study (P ¼ .36). The safety and low rate of readmission of the EDOM-ASCT in myeloma trial suggest that
this strategy could be extended to other transplantation centers if a stringent patient selection and appro-
priate management are applied.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy (HDC) followed by autologous
stem cell transplantation (ASCT) [1,2] remains the standard
of care for young medically ﬁt patients with multiple
myeloma (MM) [3-5]. Recent studies also suggest that
induction therapy with so-called new drugs beforeedgments on page 1031
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14.03.027transplantation may improve clinical outcomes [6,7]. In
addition, long-term disease control can be achieved with a
variety of post-transplantation consolidation [8] and main-
tenance therapies [9,10]. Up until now, it is, however, not
clear how proteasome inhibitor and immunomodulatory
drugs should be best incorporated in the transplantation
paradigm [11]. Moreover, whether ASCT should be main-
tained as an upfront strategy or delayed until relapse is a
matter of debate [12,13]. Overall, the International Myeloma
Working Group recommends that ASCT be invariably offered
at some point during the disease course for eligible young
patients [14]. Thus, MM remains the leading indication for
ASCT in Europe [15].Transplantation.
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marrow transplantation units on a “whole inpatient pro-
gram,” where central venous catheter (CVC) insertion, HDC
administration, hematopoietic progenitor cell (HPC) infu-
sion, and supportive care during neutropenia are carried out
in positive-pressure reverse isolation rooms, with a hospital
stay of approximately 3 to 4 weeks [15-17]. The growing
demand for ASCT signiﬁcantly increases waiting lists and
generates concerns about the appropriate use of health care
resources. Over the past years, a number of studies have
investigated safety, efﬁcacy, and potential cost advantages of
outpatient programs to reduce hospital stays after ASCT in
both hematological and nonhematological diseases [17]. The
early-discharge outpatient model (EDOM) is 1 of the most
common approaches. By this model, CVC insertion, ﬂuid
infusion, HDC administration, and HPC infusion are carried
out as inpatient care, whereas the management of the
aplastic phase is carried out as outpatient care. Thoughmany
reports suggest its feasibility also in lymphoma patients after
BEAM (BCNU, etoposide, cytarabine and melphalan condi-
tioning) [18,19], stringent inclusion criteria have not yet been
clearly deﬁned, and policies may greatly vary especially for
the management of the aplastic phase in the outpatient
setting and for readmission criteria. The aim of this study
was to retrospectively evaluate current policies and to
analyze clinical outcomes of EDOM-ASCT in a large cohort of
MM patients treated in Italian centers afﬁliated with the
Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO).MATERIAL AND METHODS
This retrospective study was conducted through the GITMO trial ofﬁce,
which promotes independent clinical research studies in the setting of both
autologous and allogeneic transplantation in Italy. The ﬁrst questionnaire
was mailed to 75 GITMO centers accredited for ASCT to evaluate how many
had been involved in EDOM-ASCT for MM patients between 1998 and 2012.
In all centers, eligibility to the EDOM program included availability of a
caregiver on a 24-hour basis; housing within easy reach to the trans-
plantation center (shorter than 1 hour drive); absence of multiple comor-
bidities as assessed by the treating physician; a baseline serum creatinine
value < 2 mg/dL at transplantation; adequate activities of daily living, such
as eating, cleaning, personal hygiene, and ambulation possible indepen-
dently or under the supervision of a caregiver; and informed consent for the
EDOM-ASCT program. If a given center was involved, further speciﬁc queries
included infectious prophylaxis, supportive care, criteria for hospital read-
mission, management of febrile neutropenia, and clinical outcomes.Figure 1. Retrospective Italian multicenter analysis of patients with multiple myelom
after an early discharge outpatient model between January 1998 and December 2012Overall, 55 of 75 (73.3%) answered the ﬁrst questionnaire: 49 centers
performed ASCT after the inpatient procedure and 6 had been involved in
outpatient ASCT programs according to EDOM.Endpoints
Primary endpoints were to evaluate efﬁcacy and safety of EDOM-ASCT in
terms of rates of hospital readmission before neutrophil and platelet re-
coveries and early transplantation-related mortality (TRM). Neutrophil and
platelet recoveries were deﬁned as the ﬁrst of 3 consecutive days of an
absolute neutrophil count  .5  109/L and the ﬁrst of 3 days of a platelet
count 20 109/L without transfusion support for 7 consecutive days. Early
TRMwas deﬁned asmortality from any cause other than disease progression
within 100 days from transplantation. Secondary endpoints were to inves-
tigate differences in center policies for patient inclusion criteria in EDOM-
ASCT, supportive care, hospital readmission criteria, and to collect clinical
data on incidence of infections, days of fever, hematological, and extra-
hematological toxicities, progression-free survival (PFS), and overall survival
(OS). The ultimate goal was that of collecting robust information on the
feasibility of EDOM-ASCT to help design clinical recommendations in our
country. The study was approved by the local ethics committee of the 6
participating centers and conducted according to the Declaration of
Helsinki.Statistical Analysis
Data are summarized as median and interquartile ranges or as absolute
number or percent frequency, as appropriate. The relationship between risk
factors and the odds of hospital readmission before neutrophil and platelet
recoveries were investigated by univariate and multivariate logistic regres-
sion analyses. Tested variables included gender, age, fever, World Health
Organization (WHO) grade 3 to 4mucositis, renal function (serum creatinine
level < 2 mg/dL versus  2 mg/dL), number of CD34þ cells infused,
granulocyte-colony stimulating factor (G-CSF) (ﬁlgrastim and lenograstim)
versus pegﬁlgrastrim, ﬁrst versus second transplantation, timing of trans-
plantation, conditioning regimen, and disease status at transplantation. All
variables correlated with hospital readmission with a P value of  .10 were
analyzed by a multiple logistic regression model. With this strategy, the
model had adequate statistical power with at least 20 readmitted patients
for each variable added to the ﬁnal model. All P values were 2-sided at the
10% signiﬁcance level, as suggested by McDonald et al. [20]. In both uni-
variate and multivariate logistic regression models, data were expressed as
odds ratio (95% conﬁdence interval [CI] and P values). To ascertain the effect
of repeated observations in the same patients who may have undergone
more than 1 transplantation, a sensitivity analysis was performed by
restricting the focus only on the ﬁrst transplantation. A center-effect analysis
was also carried out by comparing the point estimates and the 95% CI of the
percentages of patients whowere readmitted at the participant centers. One
center (Potenza) was excluded by this analysis because of the low number of
patients enrolled (n ¼ 4). OS and progression-free survival curves were
estimated by the Kaplan-Meier method. Data analysis was performed by
SPSS for windows (version 20.0.0, IBM, Armonk, NY).a who underwent an autologous hemopoietic progenitor cell transplantation
.
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Overall, between January 1998 and December 2012, 536
EDOM-ASCT procedures for 382 MM patients were per-
formed at Italian GITMO centers. Fourteen cases (2.6%) with
incomplete data set for the evaluation of primary endpoints
of the study were excluded from the analysis, leaving 522
eligible, representing the body of this paper. Center activities
are illustrated in Figure 1 and patient characteristics are
summarized in Table 1.
Median age at transplantation was 58.7 (range, 27.5 to
75.4) years, and the majority of patients were male (66.2%).
At diagnosis, serum creatinine level was < 2 mg/dL in 270 of
382 (70.7%) patients, and  2 mg/dL in 65 of 382 (17%) [21].
Datawere missing in 47 of 382 (12.3%). Most patients (52.9%)
received vincristine, adriamycin, and dexametasoneebased
induction regimens. Response rates by the European Society
for Blood and Marrow Transplantation criteria [22]
are described in Table 1. High-dose melphalan (HDM)
200 mg/m2 (84%) or 140 mg/m2 (16%) were employed asTable 1
Characteristics of Multiple Myeloma Patients Undergoing an EDOM-ASCT
Characteristic Value
Total no. of patients 382
Sex, n (%)
Male 253 (66.2)
Female 129 (33.8)
Age, median (range), yr* 58.7 (27.5-75.4)
Gammopathies, n (%)y
IgG 209 (54.7)
IgA 79 (20.7)
Light chain 74 (19.4)
Not known 20 (5.2)
Gammopathies, n (%)z
klight chain 207 (54.2)
llight chain 145 (38.0)
Not known 30 (7.9)
Renal function (Durie and Salmon
subclassiﬁcation criteria), n (%)
Serum creatinine level < 2 mg/dL 270 (70.7)
Serum creatinine level  2 mg/dL 65 (17.0)
Not known 47 (12.3)
Induction regimen schedule, n (%)
VAD (vincristine, doxorubicin and
dexamethasone)
202 (52.9)
Velcade-based 114 (29.8)
Imids-based 55 (14.4)
Others 11 (3.2)
Up-front transplantationx, n (%) 304 (79.6)
Status after induction regimen, n (%)k
Complete response 92 (24)
Near complete response 23 (6)
Very good partial response 73 (19)
Partial response 175 (46)
Stable disease 11 (3)
Progression disease 8 (2)
Outpatient procedures
At the ﬁrst ASCT 350 (67.0)
At the ﬁrst and second ASCT 140 (26.8)
At the second ASCT 32 (6.2)
Total number of ASCT 522 (100)
Conditioning regimen, n (%)
Melphalan 200 mg/m2 437 (84)
Melphalan 140 mg/m2 85 (16)
EDOM indicates early discharge outpatient model; ASCT, autologous stem
cell transplantation.
* Data are shown as median (interquartile range).
y Measured by serum immunoﬁxation or immunoelectrophoresis.
z Measured by urine immunoﬁxation or immunoelectrophoresis.
x Transplantation at diagnosis.
k Clinical response evaluated using the European Group for Blood and
Marrow Transplantation Criteria.conditioning. All patients received HPC with a median dose
of CD34þ cells of 5.0 (range, 1.2 to 15.0)  106/kg. Discharge
after the HPC infusion occurred at a median of 1 day (range,
0 to 3).Supportive Care
During the aplastic phase, all patients received oral pro-
phylaxis with ciproﬂoxacin at 500 mg twice daily or levo-
ﬂoxacin at 500 mg/day from day 0 until neutrophil recovery,
and with acyclovir at 800 mg twice daily from day þ3 post-
transplantation until approximately day þ90. Pneumocystis
Jiroveci prophylaxis with trimethoprim/sulfamethoxazole, 1
double-strength tablet 2 or 3 times weekly, was started after
hematological recovery and continued for 3 months. Anti-
fungal prophylaxis with ﬂuconazole at 400 mg/day was
started at day 0 and continued until neutrophil recovery only
in 2 centers (Milan, San Raffaele Hospital, and Naples, Car-
darelli Hospital). All centers except 1 used cryotherapy with
ice chips for the prevention of HDM-induced oral mucositits.
Patients started keeping ice chips in their mouths approxi-
mately 30 minutes before the HDM conditioning and for
about 6 hours afterwards. At the University Hospital center in
Ancona, amifostine at 750 mg/m2 was administered before
HDM conditioning to prevent mucositis. G-CSF (ﬁlgrastim or
lenograstim) at 5 mcg/kg/day was started at day þ5 until
neutrophil recovery in 217 of 522 transplantations (42%) and
single-dose pegﬁlgrastim at day þ1 in 305 of 522 trans-
plantations (58%). Red blood cell and platelet transfusions
were given to maintain hemoglobin levels > 8 mg/dL and
platelet counts >10  109/L, or in case of symptomatic ane-
mia and/or minimal muco-cutaneous hemorrhagic syn-
drome. Patients received i.v. hydration and electrolyte
support as per institutional policy.Criteria for Hospital Readmission
In all centers, criteria for readmission after early discharge
included uncontrolled nausea and/or vomiting, diarrhea and/
or severe mucositis requiring continuous ﬂuid replacement,
continuous need of parental nutrition or narcotic drugs,
pneumonia, cardiac and/or respiratory distress, patient
request, or any other toxicity judged unmanageable as
outpatient by the medical staff. Fever without hemo-
dynamic instability responsive to ﬁrst-line antibiotics was
managed on the outpatient service, except at the San Raffaele
Hospital in Milan where patients were hospitalized.Management of Febrile Neutropenia
In all centers, neutropenic fever (NF) was deﬁned as an
axillary temperature exceeding > 38.2C on at least 2
consecutive occasions or a persistent temperature of equal to
or greater than 38.0 C for at least an hour, in the absence of
any documented noninfectious cause, such as transfusion
reactions or administration of cytotoxic drugs. Neutropenia,
again, was deﬁned as absolute neutrophil count < .5  109/L
or absolute neutrophil count of 1 and a predicted decline to
less than .5 over the next 48 hours. When NF was observed,
blood and catheter cultures were set up and empiric antibi-
otic therapy was promptly started. Patients received i.v.
ceftriaxone at Cardarelli Hospital in Naples, at BMM Hospital
in Reggio Calabria, and at San Carlo Hospital in Potenza, i.v.
piperacillin-tazobactamat San Raffaele Hospital in Milan, or
oral amoxicillin and clavulanic acid at University Hospital in
Ancona.
Table 2
Outcome of EDOM-ASCT in Multiple Myeloma Patients in Italy
Value
No. of transplantations 522
CD34þ cells ( 106/kg) infused* 5 (1.2-15)
Duration of hospitalization (day)* 4 (2-9)
Day of discharge*,y 1 (0-3)
Type of G-CSF, n (%)
Filgrastim/lenograstim 217 (42)
Pegﬁlgrastim 305 (58)
Erythrocyte transfusions (units), n* 0 (0-11)
Platelet transfusions (units), n* 0 (0-7)
Engraftment (days after transplantation)*
Days to reach neutrophils >.5  109/L 10 (8-24)
Days to reach platelets > 20  109/L 12 (8-36)
EDOM indicates early-discharge outpatient model; ASCT, autologous stem
cell transplantation.
* Data are shown as median (interquartile range).
y Day of discharge after transplantation, ie, day 0 is the day of stem-cell
reinfusion.
Table 3
Toxicity of EDOM-ASCT in Multiple Myeloma Patients in Italy
Value
No. of transplantations 522
Fever  38.2C, n (%) 161 (30.8)
Fever origin, n (%)
FUO 132 (82.0)
CVC related 10 (6.2)
Clinically documented 13 (8.0)
Microbiologically documented infection 6 (4.0)
No. of days of fever  38.2C* 3 (1-22)
No. of days antibiotic therapy* 6 (0-25)
Mucositis grade 3-4, n (%) 50 (9.6)
Readmitted before ANC > .5, n (%) 98 (18.8)
Reasons for readmission to hospital, n (%)
Febrile neutropenia 76 (14.6)
Mucositis 9 (1.7)
Diarrhea 9 (1.7)
Arrhythmia 2 (.4)
Transit ischemic attack 1 (.2)
Cutaneous hemorrhage 1 (.2)
Duration of second hospitalization, d* 8 (1-30)
EDOM indicates early discharge outpatient model; ASCT, autologous stem
cell transplantation; ANC, absolute neutrophil count; CVC, central venous
catheter; FUO, fever of unknown origin.
* Data are shown as median (interquartile range).
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Median day of discharge was day 1 (range, 0 to 3) after
HPC reinfusion. Neutrophil and platelet engraftment
occurred in all patients at a median of 10 (range, 8 to 24) and
12 days (range, 8 to 36 days) after ASCT, respectively. Median
numbers of transfused red blood cell and platelet units were
0 (range, 0 to 11 units) and 0 (range, 0 to 7 units), respectively
(Table 2). Transfusion support was not statistically different
in the setting of patients who required a rehospitalization
(data not shown). Readmission until neutrophil and platelet
recovery was required in 98 out of 522 transplantations
(18.8%) (Figure 1). Readmission rates did not signiﬁcantly
differ among the centers and a center effect was not observed
(Figure 2). The major extrahematological complication was
NF in 161 cases (30.8%) and was the main reason for read-
mission in 76 cases, whereas the remaining 85 cases were
managed as outpatients. Median number of days of fever and
antibiotic therapy was 3 (range, 1 to 22) and 6 (range, 0 to
25), respectively. In most cases (82%), no documented in-
fections were reported. Infections documented by blood and/
or urine or sputum cultures, or suggested by imaging studies,
such as chest radiographs, and physical examination (ie,
cellulites around the catheter exit sites) in the absence of
positive cultures, were reported in 4% and 8% of febrile
episodes, respectively. In 6.2% of cases, cultures from
indwelling intravenous catheters yielded coagulase-negativeFigure 2. Readmission before engraftment (neutrophils > .5  109/L and
platelets > 20  109/L).Staphylococci CVC-related infections. In the remaining 361
procedures (69.2%), no fever was reported during neu-
tropenia. No systemic fungal infections, either possible or
probable, could be documented. Severe WHO 3 to 4 muco-
sitis, according to theWHO’s grading scale [23], was reported
in 50 cases (9.6%). Other extrahematological toxicities were
infrequent and rarely caused readmission (Table 3). Five
patients (1%) died within 100 days from transplantation. One
patient, readmitted 4 days after discharge for NF, died on day
25 after ASCT for hemorrhagic stroke. Three patients died of
sepsis: 1, readmitted at day 5, died of sepsis and respiratory
failure on day 30; 1 died on day 7 with documented infection
by Escheria coli, and in another, who died on day 15, no
pathogen was identiﬁed. One additional patient developed a
clinically documented infection (pneumonia) and died on
day 12 after ASCT. In all cases, autopsy was not performed.
Risk Factors for Readmission
By univariate analysis, gender, age at transplantation,
number of CD34þ infused, type of myeloid growth factor,
conditioning regimen, and disease status at transplantation
had no impact on readmission rate, whereas fever, mucositis,
renal function (creatinine level  2 mg/dL at diagnosis),
number of ASCT procedures (second), and timing of trans-
plantation (ie, late in the course of the disease, not upfront)
were signiﬁcantly associated with readmission (Table 4).
However, by multivariate analysis, only fever, mucositis,
altered renal function, and timing of transplantation
remained independent predictors. These ﬁndings were also
conﬁrmed by a sensitivity analysis carried out on patient
characteristics at the ﬁrst transplantation (see Table 4).
Clinical Outcomes
At a median follow-up of 200 months, OS and PFS were
85 months (95% CI, 76 to 93) and 34 months (95% CI, 29 to
38), respectively. At follow-up, 20% of the patients were alive
and 18% had not progressed (Figure 3).
DISCUSSION
The aim of this study was to evaluate the current role of
EDOM-ASCT and to analyze clinical outcomes on a large
Table 4
Univariate and Logistic Multivariate Regression Analysis of Risk Factors for Readmission before Neutrophil and Platelet Engraftment
Risk Factor Odds Ratio (95% CI) and P Value for Readmission
Univariate Analysis Multivariate Analysis*
Female gender 1.39 (.88-2.19), P ¼ .16 –
Age, yr 1.02 (.99-1.05), P ¼ .21 —
Fever (yes versus no) 12.9 (7.7-21.8), P < .001 10.3 (5.2-20.4), P < .001
Mucositis WHO 3-4 (yes versus no) 6.5 (3.5-12.4), P < .001 5.7 (2.6-12.3), P < .001
Renal function (sCr  2 mg/dL versus <2 mg/dL) at diagnosis 1.62 (.92-2.85), P ¼ .09 2.21 (.99-4.90), P ¼ .05
CD34þ cells ( 106/kg) infused (5 versus < 5) .90 (.58-1.40), P ¼ .64 —
G-CSF versus pegﬁlgrastim .72 (.46-1.12), P ¼ .15 —
Number of transplantations (second versus ﬁrst) .67 (.41-1.09), P ¼ .10 .64 (.31-1.30), P ¼ .22
Timing of transplantation (up-front versus delayed) .61 (.37-1.00), P ¼ .05 .35 (.15-.81), P ¼ .01
Conditioning regimen (Mel 140 versus 200) 1.29 (.74-2.25), P ¼ .37 ——
Status at transplantation
Complete remissiony 1 ——
Near complete remission .54 (.13-2.22), P ¼ .40
Very good partial remission 1.14 (.25-5.33), P ¼ .87
Partial remission .34 (.08-1.48), P ¼ .15
Stable disease .69 (.18-2.69), P ¼ .59
Progression 1.08 (.18-6.21), P ¼ .94
sCr indicates serum creatinine; WHO, World Health Organization; G-CSF, granulocyte-colony stimulating factor (ﬁlgrastim or lenograstim), Mel, melphalan; CI,
conﬁdence interval.
A sensitivity analysis considering patients characteristics at the ﬁrst transplantation conﬁrmed fever (odds ratio [OR], 12.6; 95% CI, 6 to 26; P < .001), mucositis
WHO 3 to 4 (OR, 9.5; 95% CI, 3.8 to 23.7; P < .001), renal function (OR, 2.4; 95% CI, 1.01 to 5.2; P ¼ .03), and timing of transplantation (OR, .40; 95% CI, .17 to .97;
P < .043) as independent correlates of readmission.
* We included into the multivariate model all variables with P < .10 at univariate analyses.
y Reference group.
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MM treatment. Despite the retrospective nature of the study,
it was rather remarkable to observe that the centers involved
shared similar patient selection criteria, antimicrobial pro-
phylaxis, and hospital readmission strategies.
The weakness of the study is the lack of a control group. A
formal randomization could not be carried out, given that the
primary endpoint was the feasibility of the EDOM-ASCT
program and a retrospective data collection for a case-
match analysis would not be possible in all centers.
However, the data reported here, in terms of outcome,
engraftment kinetics, TRM, and toxicity, are comparable with
the main series recently reported in the literature [11,14,24].
Several manuscripts have already demonstrated that the
outpatient program is feasible [17] and, in some studies, a
clinical advantage has been shown as well as the saving of
ﬁnancial resources [25-27]. Our paper, through the analysis
of a remarkable number of transplantation proceduresFigure 3. Kaplan-Meier estimates of overall survival (A) and pperformed in the Italian centers, is focused on the optimi-
zation of the EDOM-ASCT. Therefore, we believe the only
meaningful comparison (besides the description of our re-
sults) should be performed with similar studies published in
the literature. Speciﬁcally, in our study, we showed that a
high degree of standardized EDOM-ASCT procedures among
GITMO centers is feasible, with no signiﬁcant differences in
readmission and TRM rates. Center effects may often repre-
sent an important bias in retrospective multicenter studies.
Epidemiologists formally assess a potential center effect by
comparing point estimates of given variables and corre-
sponding 95% CI. A center effect can reasonably be excluded
when CI largely overlap [28]. Large overlapping areas of CI
were seen in our analysis, indicating that clinical outcomes
were not center dependent (Figure 2).
Overall, unlike other reports [16,18,29-34], our read-
mission rate,18.8%, was quite low. This may be explained by a
number of reasons.rogression-free survival (B) in the evaluable population.
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tered. A recent meta-analysis [35] of 109 randomized trials in
patients who developed neutropenia without fever showed
that those with hematological malignancies and/or under-
going HPC transplantation were at higher risk of read-
mission. Moreover, a lower all-cause mortality was seen in
patients on antimicrobial prophylaxis as compared with
those who were not. Fernandez Aviles [36] reported a very
low readmission rate, 8%, by introducing ceftriaxone pro-
phylaxis in 50 patients with different hematological malig-
nancies, although, in this study, the early discharged patients
were selected in the light of their Eastern Cooperative
Oncology Group performance status (<2). Finally, other re-
ports have shown a signiﬁcant reduction in mortality by
adding prophylaxis with quinolones [37].
Second, the outpatient management of NF in most cases
with oral antibiotics or once-daily i.v. antibiotics largely
contributed to the low readmission rate, that, in turn, highly
limited the risk of exposure tomultidrug-resistant organisms
commonly found on hospital wards [38]. In our experience,
only patients with NF and/or documented infections associ-
ated with hemodynamic instability were hospitalized. A
recently published retrospective analysis on EDOM-ASCT in
91 MM patients by a Canadian group [18] concluded that the
procedure is safe and cost effective when performed in a
weekday clinic, though it is associated with a high read-
mission rate, 84%, especially in patients over 60 and with
disease stage IIB or higher. The high rate may be explained by
the inclusion of patients with advanced disease and different
NF management. A policy similar to Canadian group for NF
management was reported in a retrospective study by Kassar
et al. [33], where 58% of the patients receiving ASCT required
hospitalization.
Third, our very lowrateofWHOgrade3 to 4oralmucositis,
frequently associated with NF and/or infections [31,39] may
likely be due to cryotherapy (administered in 371 patients) or
to the use of amifostine (151 patients). A recent Cochrane
review showed that cryotherapy (ice chips) and the admin-
istration of keratinocyte growth factor were of some beneﬁt
in preventing mucositis [40]. In our study, though not statis-
tically signiﬁcant, a lower incidence of severe mucositis was
observed at the University Hospital of Ancona, where ami-
fostine was routinely used a cyto-protector. However, it did
not signiﬁcantly affect the probability of readmission. Ami-
fostine detoxiﬁes reactive metabolites of platinum and alky-
lating agents [41] and its potential role in preventing
extrahematological toxicity after HDM has been investigated
in many studies, with contrasting results [42].
Although our experience includes patients who under-
went transplantation over 10 years ago, no major changes in
supportive care were introduced over the study period. One
change was the introduction of long-active growth factors.
Pegﬁlgrastim was often chosen to favor patient compliance,
given its single dose at 6 mg s.c. rather than daily doses
of either ﬁlgrastim or lenograstim. A systematic review
comparing G-CSF and pegﬁlgrastim in the autologous setting,
including a randomized trial of 80 patients, concluded that
the 2 growth factors are at least equally effective [43].
Overall, the ﬁrst experiences of “outpatient autografts”
were reported in North America with readmission rates of
30% [29] and 61% [30]. Faucher et al. [16] reported a rate of
86% in the ﬁrst randomized study comparing EDOM with
standard inpatient ASCT in a cohort of 131 patients with
nonleukemic malignant diseases. Of note, 33% of patients
could not be discharged early because of social orpsychological reasons, such as lack of a caregiver or living far
away from the transplantation center. In another study by
Gertz et al. [34], only 39% of 716 patients completed the
procedure without readmission. Patient age (>65 years) and
serum creatinine level (1.5 mg/dL) were associated with
higher risk of readmission. We think that the stringent
application of inclusion criteria, such as normal serum
creatinine at the time of transplantation, the availability of a
full-time caregiver, and living within 1-hour drive to the
transplantation center, formed the basis for the low read-
mission rate reported by our centers.
Our study was not designed to carry out a detailed cost
analysis. However, several studies showed that outpatient
models of autografting are highly cost effective, mainly
because of shorter duration of hospitalization and reduced
drug administration and laboratory costs [25-27,30]. One
prospective randomized study comparing an outpatient
model with conventional inpatient ASCT [16] in patients with
malignancies reported an estimated cost saving of 19%. A
recent Italian study [19] focused on EDOM in lymphoma
patients, conditioned with BEAM (BCNU, etoposide, cytar-
abine and melphalan) and given amifostine to reduce
extrahematological toxicity, reported a very low incidence of
severe mucositis and the outpatient treatment plan was
successfully completed in two thirds of the patients. Overall,
only 26% required a short readmission and this translated
into signiﬁcant cost saving.
In conclusion, this paper showed a high degree of stan-
dardized EDOM procedures among the GITMO centers. The
safety and low readmission rates may likely have been due to
stringent selection criteria. Ideal candidates appeared to be
thosewith goodperformance status, a full-time caregiver, and
thosewho lived near the transplantation center.Moreover, NF
could safely be managed in the outpatient service and the
administration of cyto-protectors may have reduced the
severity of mucositis and its symptoms. The detailed analysis
of these clinical parameters represents the novelty of the
paper and makes, in our opinion, this work potentially valu-
able for clinical transplantation providers. However, our
results do not allow us to extensively recommend the EDOM-
ASCT program, outside a national policy, and in centers which
do not fulﬁll the criteria of an adequate skilled team and
adequate logistics for the managing these patients. Future
trials should focus on large prospective multicenter outpa-
tient programs, which may identify patient subgroups who
most beneﬁt fromthis innovative andcost-effective approach.
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